Pasithea Therapeutics Corp (NASDAQ: KTTA) has announced that its wholly-owned subsidiary, Pasithea Clinics, has given the first patients intravenous ketamine therapy. Ketamine has been demonstrated to be particularly successful in treating several mental diseases, such as post-traumatic stress disorder and treatment-resistant depression, in sub-anesthetic doses.
Category Press Release
Country United States of America
Companies Featured
Pasithea TherapeuticsPasithea Therapeutics is a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders.